View source for 18280126. METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)

=METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL=


==Organization Name==

[[:Category:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY|THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY]]


[[Category:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY]]

==Inventor(s)==

[[:Category:Shane Liddelow of New York NY (US)|Shane Liddelow of New York NY (US)]][[Category:Shane Liddelow of New York NY (US)]]

[[:Category:Kevin Guttenplan of Portland OR (US)|Kevin Guttenplan of Portland OR (US)]][[Category:Kevin Guttenplan of Portland OR (US)]]

[[:Category:Ben Barres (deceased) of Palo Alto CA (US)|Ben Barres (deceased) of Palo Alto CA (US)]][[Category:Ben Barres (deceased) of Palo Alto CA (US)]]

==METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18280126 titled 'METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL

==Simplified Explanation==

The present disclosure relates to methods of inhibiting reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in a subject. In one embodiment, the method involves administering an inhibitor of Elongation of Very Long Chain Fatty Acids Protein 1 (ELOVL1) to a subject having or at risk of having a condition mediated by reactive astrocytes, where the ELOVL1 inhibitor is administered in an amount effective to inhibit reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in the subject. In another embodiment, the method involves administering an inhibitor of lipoapoptosis to a subject having or at risk of having a condition mediated by reactive astrocytes, where the inhibitor of lipoapoptosis is administered in an amount effective to inhibit reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in the subject.

* Inhibiting reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in a subject
* Administering an inhibitor of ELOVL1 or lipoapoptosis to a subject with a condition mediated by reactive astrocytes

== Potential Applications ==
The technology can be applied in the treatment of conditions involving reactive astrocytes, such as neurodegenerative diseases.

== Problems Solved ==
This technology addresses the issue of neuronal and oligodendrocyte cell death mediated by reactive astrocytes, which can lead to various neurological disorders.

== Benefits ==
The method offers a potential way to prevent cell death in the central nervous system, improving overall neurological health and function.

== Potential Commercial Applications ==
The technology could be utilized in the development of novel therapeutics for neurodegenerative diseases, potentially leading to new treatment options for patients.

== Possible Prior Art ==
Previous research may have explored the role of astrocytes in neurodegenerative diseases and potential therapeutic targets, but specific inhibitors of ELOVL1 or lipoapoptosis may be novel in this context.

=== Unanswered Questions ===

=== How does the inhibitor of ELOVL1 work at a molecular level to inhibit reactive astrocyte mediated cell death? ===

The specific mechanism of action of the ELOVL1 inhibitor in preventing cell death mediated by reactive astrocytes is not detailed in the abstract. Further research may be needed to elucidate this process.

=== Are there any potential side effects or limitations associated with the administration of these inhibitors in a clinical setting? ===

The abstract does not mention any potential drawbacks or limitations of using ELOVL1 or lipoapoptosis inhibitors in patients. Additional studies may be necessary to assess the safety and efficacy of these inhibitors in a clinical setting.


==Original Abstract Submitted==

The present disclosure relates to methods of inhibiting reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in a subject. In one embodiment, the method involves administering an inhibitor of Elongation of Very Long Chain Fatty Acids Protein 1 (ELOVL1) to a subject having or at risk of having a condition mediated by reactive astrocytes, where the ELOVL1 inhibitor is administered in an amount effective to inhibit reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in the subject. In another embodiment, the method involves administering an inhibitor of lipoapoptosis to a subject having or at risk of having a condition mediated by reactive astrocytes, where the inhibitor of lipoapoptosis is administered in an amount effective to inhibit reactive astrocyte mediate neuronal and/or oligodendrocyte cell death in the subject.



[[Category:A61K31/496]]
[[Category:A61K31/192]]
[[Category:A61K31/201]]
[[Category:A61K31/436]]
[[Category:C12N15/113]]